The voluntary recall stems from infections from a single donor lot, according to a news release. Before release, samples from the lot had tested negative for tuberculosis.
Aziyo Biologics is cooperating and investigating with the FDA and CDC, the company said. Shipping for all viable bone matrix products from all donor lots was suspended. Aziyo Biologics is also working to notify patients who received bone matrix products from the affected donor lot.
Two years ago, Aziyo Biologics recalled another bone repair product, FiberCel, after multiple patients tested positive for tuberculosis.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
